A5019526778- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Innovative Energy Harvesting Technologies
- Blood disorders and treatments
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Esophagitis
- Energy Harvesting in Wireless Networks
- Helicobacter pylori-related gastroenterology studies
- Advanced Multi-Objective Optimization Algorithms
- Control Systems and Identification
- Statistical Methods in Clinical Trials
- interferon and immune responses
- Aerodynamics and Fluid Dynamics Research
- Manufacturing Process and Optimization
- Fault Detection and Control Systems
- Gene Regulatory Network Analysis
- Vibration Control and Rheological Fluids
- Childhood Cancer Survivors' Quality of Life
- Simulation Techniques and Applications
- Advanced Combustion Engine Technologies
- Real-Time Systems Scheduling
Sanofi (Germany)
2023
Otto-von-Guericke University Magdeburg
2016-2023
Boehringer Ingelheim (Germany)
2021
TU Dortmund University
2017
University of Pisa
2017
Robert Bosch (Taiwan)
2017
Chalmers University of Technology
2017
Polytechnique Montréal
2017
Abstract Purpose Infections due to severe neutropenia are the most common therapy-associated causes of mortality in patients with acute myeloid leukemia (AML). New strategies lessen severity and duration needed. Methods Cytarabine is commonly used for AML consolidation therapy; we compared high- intermediate-dose cytarabine administration on days 1, 2, 3 (AC-123) versus 3, 5 (AC-135) therapy AML. Recently, clinical trials demonstrated that high-dose AC-123 resulted a shortened white blood...
We investigate the personalisation and prediction accuracy of mathematical models for white blood cell (WBC) count dynamics during consolidation treatment using intermediate or high-dose cytarabine (Ara-C) in acute myeloid leukaemia (AML). Ara-C is clinically most relevant cytotoxic agent AML treatment. extend a model myelosuppression pharmacokinetic with different hypotheses Ara-C's pharmacodynamic effects. cross-validate 12 variations dense WBC measurements from 23 patients. Surprisingly,...
Mouse and human data implicate the NOD1 NOD2 sensors of intestinal microbiome associated signal transduction via receptor interacting protein kinase 2 (RIPK2) as a potential key signaling node for development inflammatory bowel disease (IBD) an attractive target pharmacological intervention. The TRUC mouse model IBD was strongly indicated evaluating RIPK2 antagonism its effect on inflammation based previous knockout studies with NOD1, NOD2, RIPK2. We identified profiled BI 706039 molecule...
Acute lymphoblastic leukemia is the most common malignancy in childhood. Successful treatment requires initial high-intensity chemotherapy, followed by low-intensity oral maintenance therapy with 6-mercaptopurine (6MP) and methotrexate (MTX) until 2-3 years after disease onset. However, intra- interindividual variability pharmacokinetics (PK) pharmacodynamics (PD) of 6MP MTX make it challenging to balance desired antileukemic effects undesired excessive myelosuppression during therapy. A...
Nonlinear model predictive control has been established as a powerful methodology to provide feedback for dynamic processes over the last decades. In practice it is usually combined with parameter and state estimation techniques, which allows cope uncertainty on many levels. To reduce also suggested include optimal experimental design into sequential process of calculation. Most focus so far was dual approaches, i.e., using controls simultaneously excite system dynamics (learning) well...
Neutropenia is an adverse event commonly arising during intensive chemotherapy of acute myeloid leukemia (AML). It often associated with infectious complications. Mathematical modeling, simulation, and optimization the treatment process would be a valuable tool to support clinical decision making, potentially resulting in less severe side effects deeper remissions. However, until now, there has been no validated mathematical model available simulate effect on white blood cell (WBC) counts...
Abstract Acute lymphoblastic leukemia is the most common malignancy in childhood and requires prolonged oral maintenance chemotherapy to prevent disease relapse after remission induction with intensive intravenous chemotherapy. In therapy, drug doses of 6-mercaptopurine (6-MP) methotrexate (MTX) are adjusted achieve sustained antileukemic activity without excessive myelosuppression. However, uncertainty exists regarding timing extent dose responses optimal adaptation strategies. We propose a...
Leukopenia is one of the most harmful side effects during chemotherapy treatment, since leukocytes (L) are crucial in protecting patients against bacteria and fungi. A personalized mathematical model dynamics L would allow a glimpse into future initiation tailored countermeasures. We propose such calibrate it based on parameter estimation with real world data. For our study we used data after consolidation treatment (cytarabine) six contracting acute myeloid leukemia. compare two different...
We present a novel derivative-based parameter identification method to improve the precision at tool center point of an industrial manipulator. The is directly considered in optimization as part problem formulation key performance indicator. Additionally, our proposed takes collision avoidance special nonlinear constraints into account and therefore suitable for use. performed numerical experiments show that optimum experimental designs considering indicators during achieve significant...
This work is devoted to demonstration of the analysis on optimizing output power harvested from vibration energy harvester.
Mathematical models are essential for simulation-driven decision support clinical doctors. For an estimation of parameters patient specific models, values such as the number certain blood cells need to be measured. In this paper we focus on leukopenia, a clinically important side effect arising from treatment leukemia with chemotherapy. A mathematical leukopenia model is presented describing dynamics leukocytes and show that standard deviations parameter estimates depend strongly timing...
Abstract We investigate the personalisation and prediction accuracy of mathematical models for white blood cell (WBC) count dynamics during consolidation treatment using intermediate or high-dose cytarabine (Ara-C) in acute myeloid leukemia (AML). Ara-C is clinically most relevant cytotoxic agent AML treatment. extend gold-standard model myelosuppression a pharmacokinetic with different hypotheses Ara-C’s pharmacodynamic effects. cross-validate 12 dense WBC measurements from 23 patients....
Acute lymphoblastic leukemia is the most common malignancy in childhood. Successful treatment requires initial high-intensity chemotherapy, followed by low-intensity oral maintenance therapy with 6-mercaptopurine (6MP) and methotrexate (MTX) until 2-3 years after disease onset. However, intra- interindividual variability pharmacokinetics (PK) pharmacodynamics (PD) of 6MP MTX make it challenging to balance desired antileukemic effects undesired excessive myelosuppression during therapy. A...
Neutropenia is an adverse event commonly arising during intensive chemotherapy of acute myeloid leukemia (AML). It often associated with infectious complications. Mathematical modeling, simulation, and optimization the treatment process would be a valuable tool to support clinical decision making, potentially resulting in less severe side effects deeper remissions. However, until now, there has been no validated mathematical model available simulate effect on white blood cell (WBC) counts...